(406) Co-delivery of TLR7/8 agonist and Dox using targeted liposome nanocarrier for bladder cancer therapy

Bladder cancer remains a significant global health burden, with 61,700 deaths estimated in the U.S. in 2022 [1]. Chemotherapy and immunotherapy are standard cancer treatments, and their combination is increasingly used. Liposome nanoparticles (LP NPs) enable the co-delivery of chemoimmunomotheraputic agent. Chitosan can enhance cellular uptake of NPs due to its cationic charge, while 4-carboxyphenylboronic acid (CPBA) selectively binds to sialic acid on bladder cancer cells. This study aims to develop a targeted liposome nanocarrier for co-delivery of Dox and R848 for bladder tumor therapy.